Immatics N.V.(IMTX) - 2021 Q4 - Annual Report

Exhibit 99.1 PRESS RELEASE Immatics Announces Full Year 2021 Financial Results and Corporate Update Tuebingen, Germany and Houston, TX, March 23, 2022 – Immatics N.V. (NASDAQ: IMTX; "Immatics"), a clinical-stage biopharmaceutical company active in the discovery and development of T cell redirecting cancer immunotherapies, today provided an update on its corporate progress and reported financial results for the quarter and full year ended December 31, 2021. Harpreet Singh, Ph.D., CEO and Co-Founder of Immati ...